Truxima Injection, Solution
Product Images NDC 63459-104

5 FDA label images from Cephalon, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Truxima (NDC 63459-104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cephalon, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure1)

Figure 1 (Figure1)
A Kaplan-Meier survival curve showing progression-free survival probability over months for two groups: Observation (red solid line) and Rituximab (blue dashed line). The x-axis represents time in months, and the y-axis shows the probability of progression-free survival. The graph includes sample sizes for each group with numbers at risk indicated below the x-axis.*
FDA Label Image

Figure 2 (Figure2)

Figure 2 (Figure2)
A line graph depicting percent ACR 20 responders over 24 weeks comparing rituximab 2x1000 mg to placebo. The X-axis represents weeks from 0 to 24. The Y-axis shows percent responders from 0 to 100. Rituximab shows higher and sustained response rates than placebo throughout the study period.*
FDA Label Image

Figure 3 (Figure3)

Figure 3 (Figure3)
A Kaplan-Meier survival curve chart comparing the percentage of patients with first major relapse over survival time in months for azathioprine (red dashed line) and rituximab (blue solid line). The chart includes numbers of subjects with major relapse and at risk for each treatment group at various time points up to 28 months.*
FDA Label Image

Figure 4 (Figure4)

Figure 4 (Figure4)
Truxima (rituximab-abbs) Injection label showing strength 100 mg/10 mL (10 mg/mL) for intravenous use after dilution. The label instructs on single-dose vial usage, discarding unused portions, and includes a notice to pharmacists to provide the enclosed medication guide. The labeler is Cephalon, Inc., with the Teva logo present.*
FDA Label Image

Figure 5 (Figure5)

Figure 5 (Figure5)
Label for Truxima (rituximab-abbs) injection, 500 mg/50 mL (10 mg/mL) solution for intravenous use. The label indicates it is a single-dose vial for use after dilution, with directions to discard unused portions. Manufacturer listed as Teva. Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.